Drug
Avexitide clinical trials
Also written Exendin (9-39).
Includes 1 study of Avexitide acetate.
- studies test it
- 36
- open now
- 6
- in phase 3
- 4
- first study started
- 1999
Keep track of what changes. Save the avexitide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
36 studies that test it; most in 2014 (5)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 11
- Phase 2
- 10
- Phase 3
- 4
- Phase 4
- 2
- No phase
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 34
Mayo Clinic (7) · Diva De Leon (4) · Adrian Vella (3) · Tracey McLaughlin (3) · The University of Texas Health Science Center at San Antonio (3) · University Hospital, Gentofte, Copenhagen (2) · Ludwig-Maximilians - University of Munich (2) · Amylyx Pharmaceuticals Inc. (1)
Often tested with
Tested in the same studies.
Atropine (3) · Glucagon-Like Peptide 1 (2) · Acarbose (1) · Metformin (1) · Pegvisomant (1) · Omega-N-Methylarginine (1) · Sitagliptin (1) · Gastric Inhibitory Polypeptide (1)
Studies
Open first, then newest update. How each study uses avexitide is read from its arms, and is right about nine times in ten.
Testing it · 36
- Islet Function in Gestational DiabetesRecruitingPhase 1Mayo ClinicNCT07806695Written as Exendin 9-39
- The Effect of rs7903146 Genotype on Islet GLP-1 Production in HumansNot yet recruitingPhase 2Mayo ClinicNCT06972407Written as Exendin 9-39
- The Role of Islet GLP-1 in the Pathogenesis of PrediabetesRecruitingPhase 2Mayo ClinicNCT06967558Written as Exendin 9-39
- The Effects of Bariatric Surgeries on Glucose MetabolismRecruitingEarly Phase 1The University of Texas Health Science Center at San AntonioNCT02823665Written as Exendin-(9-39)
- Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass SurgeryRecruitingEarly Phase 1The University of Texas Health Science Center at San AntonioNCT00992901Written as Exendin-(9-39)
- Glucagon-like Peptide 1, Glucose Metabolism and Gastric BypassRecruitingEarly Phase 1The University of Texas Health Science Center at San AntonioNCT01803451Written as exendin-(9-39)
- Avexitide for Treatment of Post-Bariatric HypoglycemiaActive, not recruitingPhase 3Amylyx Pharmaceuticals Inc.NCT06747468Written as Avexitide
- The Effect of Endogenous GLP-1 on Glucagon Secretion in Type 1 DiabetesCompletedNot applicableAsger Lund, MDNCT07373236Written as exendin(9-39)amide
- A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in NondiabeticsCompletedPhase 3Adrian VellaNCT04466566Written as Exendin-9,39
- Regulation of Insulin Secretion by the GLP-1 ReceptorTerminatedPhase 4VA Office of Research and DevelopmentNCT02844907Written as Exendin (9-39)
- Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric HypoglycemiaCompletedPhase 1Tracey McLaughlinNCT02996812Written as Exendin (9-39)
- Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric SurgeryTerminatedPhase 1Tracey McLaughlinNCT02550145Written as Exendin (9-39)
- Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 DiabetesCompletedPhase 3Adrian VellaNCT04466618Written as Exendin-9,39
- A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin SecretionCompletedPhase 3Adrian VellaNCT04459338Written as Exendin-9,39
- Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic HypoglycemiaCompletedPhase 2Dr. Tracey McLaughlin, MDNCT04652479Written as Avexitide
- Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric HypoglycemiaCompletedPhase 2Eiger BioPharmaceuticalsNCT03373435Written as exendin 9-39
- The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 DiabetesCompletedPhase 2Mayo ClinicNCT02762708Written as Exendin-9,39
- Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric HypoglycemiaCompletedPhase 2Tracey McLaughlinNCT02771574Written as Lyo avexitide
- Effect of Exendin (9-39) on Glucose Requirements to Maintain EuglycemiaTerminatedPhase 1/2Diva De LeonNCT00835328Written as Exendin (9-39)
- Exendin-9,39 and Satiety After Bariatric SurgeryCompletedNot applicableMayo ClinicNCT02779075Written as Exendin-9,39
See all 36 studies that test avexitide →
Given in every arm · 2 — avexitide is usual care beside what is tested
- Cardiovascular Effects of GLP-1 Receptor ActivationCompletedPhase 4Vanderbilt University Medical CenterNCT03101930Written as Exendin (9-39)
- The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and PrediabetesCompletedPhase 4Carl T. Hayden VA Medical CenterNCT01181986Written as Exendin-9
As the comparator · 1 — what is tested is compared with avexitide
Codes
What other systems call avexitide · ClinicalTrials.gg INT003753
- MeSH (NLM) C083773exendin (9-39)Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 5313W10MYTAVEXITIDEConfirmed FDA, NLM
- NCI Thesaurus C133230AvexitideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C083773 | exendin (9-39) | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 5313W10MYT | AVEXITIDE | Confirmed FDA, NLM |
| NCI Thesaurus | C133230 | Avexitide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.